19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers A five-protein signature could help predict the risk of ischemic stroke, MI and death from cardiovascular events in atherosclerosis patients. In serum samples from 282 patients and 403 healthy volunteers, a protein...
17:50 , Dec 1, 2016 |  BC Innovations  |  Translation in Brief

Off BACE

With November’s Phase III failure of Eli Lilly and Co. ’s (NYSE:LLY) β-amyloid inhibitor solanezumab for Alzheimer’s disease, and the pharma’s announcement last week that it was abandoning efforts to submit the compound for regulatory...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cathepsin B; cathepsin L (CTSL); α-synuclein (SNCA)

Neurology INDICATION: Parkinson's disease (PD) In vitro studies suggest activating cathepsin L and cathepsin B could help treat PD. In lysosomal extracts from mouse liver and brain cells, cathepsin L and cathepsin B cleaved SNCA...
07:00 , Jun 4, 2012 |  BioCentury  |  Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a...